- Home
- JSPR vs RNXT Comparison
JSPR vs RNXT Comparison
Compare JSPR & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JSPR
- RNXT
- Stock Information
- Founded
- JSPR 2018
- RNXT 2012
- Country
- JSPR United States
- RNXT United States
- Employees
- JSPR N/A
- RNXT N/A
- Industry
- JSPR Biotechnology: Biological Products (No Diagnostic Substances)
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- JSPR Health Care
- RNXT Health Care
- Exchange
- JSPR Nasdaq
- RNXT Nasdaq
- Market Cap
- JSPR 47.6M
- RNXT 44.6M
- IPO Year
- JSPR N/A
- RNXT 2021
- Fundamental
- Price
- JSPR $2.38
- RNXT $1.27
- Analyst Decision
- JSPR Buy
- RNXT Strong Buy
- Analyst Count
- JSPR 12
- RNXT 2
- Target Price
- JSPR $30.78
- RNXT $7.50
- AVG Volume (30 Days)
- JSPR 150.8K
- RNXT 579.5K
- Earning Date
- JSPR 11-06-2025
- RNXT 11-12-2025
- Dividend Yield
- JSPR N/A
- RNXT N/A
- EPS Growth
- JSPR N/A
- RNXT N/A
- EPS
- JSPR N/A
- RNXT N/A
- Revenue
- JSPR N/A
- RNXT $662,000.00
- Revenue This Year
- JSPR N/A
- RNXT $2,988.37
- Revenue Next Year
- JSPR N/A
- RNXT $300.60
- P/E Ratio
- JSPR N/A
- RNXT N/A
- Revenue Growth
- JSPR N/A
- RNXT N/A
- 52 Week Low
- JSPR $2.27
- RNXT $0.75
- 52 Week High
- JSPR $26.05
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- JSPR 27.23
- RNXT 60.58
- Support Level
- JSPR $2.50
- RNXT $1.06
- Resistance Level
- JSPR $2.87
- RNXT $1.45
- Average True Range (ATR)
- JSPR 0.13
- RNXT 0.11
- MACD
- JSPR -0.01
- RNXT 0.03
- Stochastic Oscillator
- JSPR 8.96
- RNXT 67.27
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.